» Articles » PMID: 26830313

Lysosomes As Mediators of Drug Resistance in Cancer

Overview
Date 2016 Feb 3
PMID 26830313
Citations 171
Authors
Affiliations
Soon will be listed here.
Abstract

Drug resistance remains a leading cause of chemotherapeutic treatment failure and cancer-related mortality. While some mechanisms of anticancer drug resistance have been well characterized, multiple mechanisms remain elusive. In this respect, passive ion trapping-based lysosomal sequestration of multiple hydrophobic weak-base chemotherapeutic agents was found to reduce the accessibility of these drugs to their target sites, resulting in a markedly reduced cytotoxic effect and drug resistance. Recently we have demonstrated that lysosomal sequestration of hydrophobic weak base drugs triggers TFEB-mediated lysosomal biogenesis resulting in an enlarged lysosomal compartment, capable of enhanced drug sequestration. This study further showed that cancer cells with an increased number of drug-accumulating lysosomes are more resistant to lysosome-sequestered drugs, suggesting a model of drug-induced lysosome-mediated chemoresistance. In addition to passive drug sequestration of hydrophobic weak base chemotherapeutics, other mechanisms of lysosome-mediated drug resistance have also been reported; these include active lysosomal drug sequestration mediated by ATP-driven transporters from the ABC superfamily, and a role for lysosomal copper transporters in cancer resistance to platinum-based chemotherapeutics. Furthermore, lysosomal exocytosis was suggested as a mechanism to facilitate the clearance of chemotherapeutics which highly accumulated in lysosomes, thus providing an additional line of resistance, supplementing the organelle entrapment of chemotherapeutics away from their target sites. Along with these mechanisms of lysosome-mediated drug resistance, several approaches were recently developed for the overcoming of drug resistance or exploiting lysosomal drug sequestration, including lysosomal photodestruction and drug-induced lysosomal membrane permeabilization. In this review we explore the current literature addressing the role of lysosomes in mediating cancer drug resistance as well as novel modalities to overcome this chemoresistance.

Citing Articles

Isowalsuranolide targets TrxR1/2 and triggers lysosomal biogenesis and autophagy via the p53-TFEB/TFE3 axis.

Yang X, Ding X, Zhao Y, Wang Y, Dong X, Niu Z Sci China Life Sci. 2025; .

PMID: 40059270 DOI: 10.1007/s11427-023-2563-6.


An aggregation-induced emission-active lysosome hijacker: Sabotaging lysosomes to boost photodynamic therapy efficacy and conquer tumor therapeutic resistance.

Zou H, Wang P, Bai Z, Liu L, Wang J, Cheng Y Mater Today Bio. 2025; 31:101564.

PMID: 40026634 PMC: 11868998. DOI: 10.1016/j.mtbio.2025.101564.


Influences of aqua-(2-formylbenzoato) triphenyltin(IV) on regression of hypoxic solid tumor through mitochondrial mediated pathway by inhibiting Hif-1 alpha.

Singh V, Singh R, Goswami P, Manna P, Basu Baul T, Mandal A Sci Rep. 2025; 15(1):5302.

PMID: 39939702 PMC: 11821849. DOI: 10.1038/s41598-025-89761-z.


Mitochondrial abnormalities as a target of intervention in acute myeloid leukemia.

Tjahjono E, Daneman M, Meika B, Revtovich A, Kirienko N Front Oncol. 2025; 14:1532857.

PMID: 39902131 PMC: 11788353. DOI: 10.3389/fonc.2024.1532857.


Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells.

Maharati A, Rajabloo Y, Moghbeli M Heliyon. 2025; 11(1):e41483.

PMID: 39834411 PMC: 11743095. DOI: 10.1016/j.heliyon.2024.e41483.